"" The Pimp Is Out For The Summer.....""Peace~ ""
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
""<<LMAO"">>....You Got That Right.... That Massive Move I Mentioned Earlier Is Underway Here On ADMD Bro!
""Mega $$$$$ On The Sidelines Waiting To Get In On ADMD Players..,Or Should I Say Struggling To Get In Because Of The Magnitude Of The Investment $$$ They Have To Put Into This BEAST!!!!
There's a Whale Spotted @ .0033 7Milly On The Bid Here On ADMD!!!!
""Massive Move Is Coming Players""...>>>ADMD Shake..,Rattle..,& Roll""
Thanks It's Worth The Time & Effort Here On ADMD""......Level Of Resistance .0036 Will Be The Area To Hold Today..., If We Do .005's Will Undoubtedly Be Seen Probably Monday.....
Thanks BH!...My Prayers Go Out To You & Yours My Friend<<<<<<<ADMD On The Cusp Of Breaking Clean & Freeeeee.......
Longtime Bro.....ADMD Invites You & Some Friends To The Greatest Show This Year Has To Offer Here On ADMD....Load'em Deeeeep Under .005 & Watch This Beast Turn Into a 500lb GORILLA""
""GM ADMD & The Players....Yesterday We Seen Action Hot & Heavy The Last 30Min Of Trading, However 15min Pryor To Closing ADMD Went NUTZ"", I Knew The 8Milly Order @ 0027 Was Going To Get Taken Out, Simply Because I Had Invited Some ""Bigg Boy Players"", Over Here To Check Out The DD That I Completed On 03/25/15 And By Doing So I Had Gotten Word That This Resistance Wall Was Coming Down & When It Did It Opened The Flood Gates Of Hell & Everybody & There Mother Came In ""LMAO..>>>>>
Those Who Sold Yesterday CONGRATS"", But Those Who Didn't Sell All Or None Of Their Position You Made a Wise Decision, Because Today You Will See SP Action Well Into The Mid To High .004's & Then Next Week We Will Top Out In The .005's Easily.....Hell We Might Even Test .005's Today!!!!
There Was a Poster Yesterday Posted The New SS:
((georgie18 Thursday, 03/26/15 01:52:42 PM
Re: pimping wallstreet post# 18944
Post # of 19118
your numbers are incorrect...I am a shareholder and just received these numbers from the TA....
YOURS...2B A/S..........correct
YOURS...554M O/S........ACTUAL...1.8 billion....minus 70M Resstricted
YOURS...443M Float.... ACTUAL..1.1 billion.....))
""How Did Ya Like That HUH?....<<<<<ADMD I Told You .0027 Was Going To Get Clobbered.....We're On Way To .005 On This Ride Till We Consolidate Again Players......See You Guys Tomorrow...>>>>>>>""Peace!
We're About To Take a Run @ .0027 Players Here On ADMD Hold On""
Until I See These Numbers In The Q My Assessment Will Remain On ADMD, And BTW Your Numbers You Just Posted Answers One Of My Questions On The Dilution Front.....Ahhhhh Yes My Friend The Float Is LOCKED!
Soon There Will No Shares To DILUTE!!!!!...>>>>""ROFLMFAO""
""Players We Must Understand That The Accumulation Here On ADMD Is UnReal....The SP Here @ .0025 Is a Joke....There Are Investors In Here Yes I Mean INVESTORS In Here That Are Thousands In DEEEEP!!!!!
The Accum/Dist Level Is Well Over 1B!...,Yes 1B! We Just Crossed That Plateau This Week.....The SS: Is
2B A/S
554M O/S
443M Float
So Yes There's Been Some (The Infamous Dilution) Since The Last Q Show Me What Penney Stock Isn't Diluting , So WHAT!!!!!, At Least These Shares Where Gobbled Up^ Bigg Time Here On ADMD & ADMD Is Not A Over Bloated Pig, Like Some Of The Others Here In Pinkyland....
ADMD Is Well Undervalued Here @ .0025 Players And There Are Some Savvy Investors In Here That Knows This Very Well That's Why They Are Loading Up^ Bigg On ADMD......Everyone Here Knows That Over The Last Few Weeks There Have Been Giant Whales Just Sucking Up Shares Like No Tomorrow I Myself Have Over 8Milly In The Bag....So Yes When I Say .05 B4 News & Nickels After News Of FDA Approval That's Exactly What I MEAN! <<<<<Mark It!
.05 B4 News Nickels As In Plural After News.....LOL~
Churning @ The Top Here Today On ADMD..<<<<<Looking Like a EOD Rally To .003 Players!.......Tomorrow Could Be Epic, Don't Miss Your Chance Of a Lifetime!!!!..>>>>ADMD Is Going Higher Much Higher SILVER At Least Before News And Nickels On News!
Excellent News!...<<<<<VOIS Finally Opening Up The Gates Of The PR"S!
Assk Slapping.....""Hey Put That 4Milly Back On The ASSK @ .0027!...<<<Don't Get Scared NOW Here On ADMD!
"ATTENTION PLAYERS" Getting Word That 8Milly Bid Will Get Wiped OUT!
""Me Too BT.......I Have Some Heavy Hitters Looking On & Possibly Have Already Entered In Here On ADMD......The DD Will Help Folks Decide Rather Or Not To INVEST In ADMD Not Swing It Or Flip It In The Coming Days & Weeks Ahead My Friend.....,So BIGG $$$$$ Is On Hand Here!
I Believe They Spreaded That Bid Out As You Can See Now On The Bid Here On ADMD @ .0025!.....They Are Loading Today And The Rest Of This Month Before April Hits!!!
Ahhhh Yes It Tis.....Stool Pigeon @ .0027 8Milly+ Better Move Here On ADMD Or Risk Being Steam Rolled OVER..<<<<<LMFAO!
Longs & The Bulls To Strong For The Two Tick Wonders Here On ADMD!
Moderate To Good Assk Slapping This Morning And Those Bid Sitters On ADMD Will Come off Of It And Join The Party!
Thanks BT.......ADMD Consolidation Period Trend Has Been Broken..,Just Like I Said It Would......Only Two Days Of Consolidation This Time Around As Opposed To 3-4 Days Worth...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112039002
Whales Sitting @ .002 5Milly+ Bid Looking Like a Block Busting Day Today!
""Monster Mega DD ADMD""
Gave You VOIS @ .0015 & Now ADMD @ .0022
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111315480
Today We Witnessed Another Whale On Bid 26Milly @ .0018 Over 47K This With Other Bids In The Past Getting Filled Over 20Milly a Pop We Can Safely Assume That There's Some Entities Out There That Are Loading Up^ Big Time Behind The Scenes Right Underneath Our Noses Players!...I Can Only Imagine What Will Happen If FDA Approval Hits & These Whales Are Still Out There Lurking Trying To Get In..
It's Going To Be Pandemonium Here On ADMD... I Can See It Know Ask Gapping Up Peeps Chasing ADMD To No End!!...Don't Let This Be YOU""
So With This In Mind Take Your Time & Decipher This Monster DD That's Laid Out In Front Of You & Maybe Then You Willl Come To Your Senses!!!!...>>LMFAO!
""Pimping Hard & Keeping The Game Real""
Corporate Overview:
Advanced Medical Isotope Corporation (AMIC) (ADMD: OTCQB) is a Kennewick, Washington-based late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. AMIC intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though AMIC will evaluate its alternatives before finalizing its plans.
Since 2006, AMIC has been focused on the commercialization of medical isotope technologies. AMIC has explored technologies for the production of medical isotopes and medical applications of isotope technologies including a line of brachytherapy products
incorporating patented technology licensed exclusively to AMIC by Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
AMIC’s robust intellectual property position includes exclusive rights under 15 patents
that cover manufacturing, processing and applications for medical isotopes.
A prominent team of radiochemists, scientists and engineers, collaborating worldwide
with strategic partners, including national laboratories, universities and private corporations,
lead AMIC’s development efforts. AMIC is proud to have been recognized as a leader in the
development of new isotope technologies by local, state and federal agencies.
Management:
Mr.Katzoroff Is a Financial Guru Players Having This Guy @ The Helm Is Huge PLUS!...& Mr.Jolliff Is The Numbers Guy, He's The One Behind The Scenes Getting The Money We Need To Get The Product To The Market!
Mr.Stevensen The Madd Scientist...This Guy Is a GENIUS"" He'll Be The One Behind The Scenes Bringing New Products To Fruition..He's a Nuclear Pysics Expert!....& Mr.Ludwig, now This Gentlemen Has International Ties Over Seas, So It's Easy To Imagine Who He Can Bring To The Table!!!!!
""Heavy Weight Mr.Su, Now This Guy Here Is The Mastermind Behind The Scenes Of The Isotope R&D Manufacturing...He Works For Pharma GIANTS"" Like Bristol-Myers Squibb..Also Working
As a Senior Scientist For Several Bio-Technology Firms, Including NeoRx, Nycomed-Amersham,And Cellectar, He Developed Various Radiopharmaceuticals, Very Impressive Savvy Scientist Players!!..,& Last But Not Lease,
Mr. Korenko.,Very..,Very Astute Intelligent Man Who Was Educated At One Of The Most Prestigious Colleges In The World ""OXFORD"" He Was Selected As a White House Fellow For The Department Of Defense Reporting To Secretary Cap Weinberger...,So Yes This Guy Has Inside Connection o The Dept Of Health And Human Services Players!!!!!
Board Of Director's:
"" Mr.Spivak What Can I Say Other Than They Call Him The Billion Dollar Man""...,Billions In Acquisitions..,Mergers..,Financing's This Guy Has Worked With Bigg Oil Mobil..,Merrill Lynch If Anybody That Can Find The $$$$$$ This Guy Can!!!!
""Mr.Cadwell Very Successful Business Man Players Co-Founded Cadwell Laboratories Privately Owned Business In 1979 And Serves As The President Till This Day....Very Savvy Business Mind Indeed!!
Visit Mr. Cadwell's Website Here Players
""Mr.Clement With His Influence Has Already Had Successful FDA Clearance With His Atrial Fibrillation Monitor, And As The CEO Of Two Very Successful Business's.., We Are Very Lucky To Have This Guy On The Board Players!
Advisory Boards:
Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Center and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, Ca.
Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.
Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard's Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography(CT).
"I am delighted to be appointed to Chair the newly formed Medical Advisory Board (MAB) for AMIC. I anticipate rapid expansion of our MAB, initially focusing on the potential for the Company's brachytherapy products," said Pressman.
James C. Katzaroff, CEO of AMIC, stated, "It is with great pleasure I welcome Dr. Pressman's guidance in assisting the Company to enter the commercial marketplace with its therapeutic products. As AMIC expands beyond the distribution and the production of stable and diagnostic radioisotopes, to the manufacturing of therapeutic products with AMIC's own product line, Dr. Pressman will be instrumental in providing a nationally-recognized practitioner's perspective and expertise that will enable the company to meet the growing needs of a dynamic nuclear medicine marketplace."
"" Mr.Fisher Is The Isotope GURU"..,Holds Several Patents Including Patents Licensed By AMIC For It's Brachytherapy Products...,Very Knowledgeable In The Isotope Field Of Technology!!!!.,& Finally Mr. Waltar Who By All Rights Holds The Key To ADMD He Has Ties With India & China, And Will Be Instrumental In Bringing The Y-90 RadioGel™ Device To Market Players!!!!!
Research & Development:
Does Nuclear Medicine Save Lives?
Yes! More than 20 million Americans benefit each year from nuclear medicine procedures used to diagnose and treat a wide variety of diseases. The use of radiation in these procedures— with low risks—offers a safe and cost-effective means to provide doctors with information that would otherwise require exploratory surgery, necessitate more costly and invasive procedures or simply be unavailable. The risks of not performing a needed medical exam are usually much greater than the risks of the radiation exposures associated with the exam.
Nuclear medicine can be used to:
determine whether or not organs are functioning normally,
show whether the blood supply to the heart is adequate,
detect cancers at an early stage,
determine the extent of cancer and assess the response of cancer to treatment,
discover whether the heart can pump blood adequately,
identify abnormal brain lesions without exploratory surgery,
detect whether the brain is receiving an adequate blood supply and if brain cells are functioning or not,
check whether or not kidneys are functioning normally and whether the stomach is emptying properly,
ascertain lung function and bone density and
locate a bone fracture before it can be seen on an X-ray.
Brachytherapy:
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.
AMIC’s Brachytherapy Products
AMIC has exclusively licensed Yttrium-90 (Y-90) polymer composite technology from *Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
Subject to receipt of all required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, AMIC plans to introduce a new Y-90-based brachytherapy product line for a range of applications for the delivery of a prescribed dose of radiation to a target site.
•Y-90 RadioGel™ device - combines Y-90 particles with a polymer carrier that may be injected directly into the tumor.
•Y-90 Fast-Resorbable Polymer Seeds - Y-90 contained within a polymer seed, as opposed to metal or glass. This product would be used in place of treating cancers with currently marketed titanium or glass seeds.
•Y-90 Polymer Topical Paste – designed to be applied directly to tissue surfaces after surgical tumor removals (also referred to as “resections”) to treat residual tumor cells..
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, AMIC believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, AMIC’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. AMIC’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. AMIC’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. The Yttrium-90 beta-emissions travel only a short distance and has a short half life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
Products:
""The Cream Of The Crop Players Yttrium 90 RadioGel™ and Polymer Seeds, Is The Future Of Radioactive Brachytherapy, And Is What We Are Waiting On The FDA To Approve....With Battelle In Our Corner There Should Be No Problem Getting This Done....(More On Battelle In a Moment)
Advanced Medical Isotope Corporation has obtained an exclusive license to eight (8) patents for injectable RadioGel™ technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The Agreement grants AMIC an exclusive license to make, have made, use and sell a RadioGel™ system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres directly into tumor tissues. The solution warms to body temperature quickly after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place. High-energy beta particles from Yttrium-90 efficiently irradiate cancer cells within the targeted volume but very little radiation escapes. This feature maximizes the overall radiation dose to cancer cells while minimizing radiation exposure and associated side-effects in nearby normal tissues.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 microspheres and the radiogel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost.
The late Dr. Robert Schenter, AMIC's Former Chief Scientific Officer, stated, "AMIC continues to develop the Yttrium-90 RadioGel™ line with Pacific Northwest National Laboratory, operated by Battelle. We believe that this product optimizes treatment of radiation-resistant tumors in vivo. We expect the RadioGel™ to become a therapeutic agent that provides physicians with the ability to effectively treat tumors that cannot be removed surgically or that cannot be treated by any other means."
According to AMIC the primary advantages of licensing these Yttrium-90 radiogels are multifold:
This treatment provides the ability to deliver a highly localized radiation therapy without irradiating nearby normal tissues - thereby achieving desired high therapeutic indices.
We are able to provide dose homogeneity within a solid tumor.
Because Yttrium-90 is a beta emitter, there is improved radiation safety for hospital personnel who prepare and handle the product.
Medical Isotopes:
AMIC is developing innovative approaches to the use, production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic applications. A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease.
The cornerstone equipment selected for the AMIC Production Facility is a proton linear accelerator. This proton linear accelerator is designed to replace large and cyclotron systems with significant infrastructure and utility requirements, such as electrical and air-handling, for the production of positron emitting isotopes. Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography. AMIC believes that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.
From 2008 through 2013, AMIC manufactured and sold F-18 FDG from its Production Facility in its local region around Kennewick, WA. F-18 is an important isotope in the radiopharmaceutical industry, and is primarily synthesized into fluorodeoxyglucose (FDG) for use in positron emission tomography (PET) scans. FDG is the primary PET imaging isotope. It is used for medical and diagnostic purposes, such as cancer detection, heart imaging, and brain imaging. AMIC’s linear accelerator is capable of producing a variety of isotopes and future manufacturing and sales could expand beyond F-18 FDG. AMIC’s accelerator is currently off-line for maintenance and is expected to resume operations in late 2014.
The FDA has 120 days in which to make a decision, though the period will be extended for any time AMIC requires to respond to FDA requests for additional information.
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.
AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products. The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue. AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy.
Battelle, has acquired approximately 11% of AMIC’s outstanding Common Stock. Battelle is a leading international science and technology enterprise that explores emerging areas of science and develops and commercializes technology.
VCEL
""Must Read...Monster Mega DD ADMD""
Today We Witnessed Another Whale On Bid 26Milly @ .0018 Over 47K This With Other Bids In The Past Getting Filled Over 20Milly a Pop We Can Safely Assume That There's Some Entities Out There That Are Loading Up^ Big Time Behind The Scenes Right Underneath Our Noses Players!...I Can Only Imagine What Will Happen If FDA Approval Hits & These Whales Are Still Out There Lurking Trying To Get In..
It's Going To Be Pandemonium Here On ADMD... I Can See It Know Ask Gapping Up Peeps Chasing ADMD To No End!!...Don't Let This Be YOU""
So With This In Mind Take Your Time & Decipher This Monster DD That's Laid Out In Front Of You & Maybe Then You Willl Come To Your Senses!!!!...>>LMFAO!
""Pimping Hard & Keeping The Game Real""
Corporate Overview:
Advanced Medical Isotope Corporation (AMIC) (ADMD: OTCQB) is a Kennewick, Washington-based late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. AMIC intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though AMIC will evaluate its alternatives before finalizing its plans.
Since 2006, AMIC has been focused on the commercialization of medical isotope technologies. AMIC has explored technologies for the production of medical isotopes and medical applications of isotope technologies including a line of brachytherapy products
incorporating patented technology licensed exclusively to AMIC by Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
AMIC’s robust intellectual property position includes exclusive rights under 15 patents
that cover manufacturing, processing and applications for medical isotopes.
A prominent team of radiochemists, scientists and engineers, collaborating worldwide
with strategic partners, including national laboratories, universities and private corporations,
lead AMIC’s development efforts. AMIC is proud to have been recognized as a leader in the
development of new isotope technologies by local, state and federal agencies.
Management:
Mr.Katzoroff Is a Financial Guru Players Having This Guy @ The Helm Is Huge PLUS!...& Mr.Jolliff Is The Numbers Guy, He's The One Behind The Scenes Getting The Money We Need To Get The Product To The Market!
Mr.Stevensen The Madd Scientist...This Guy Is a GENIUS"" He'll Be The One Behind The Scenes Bringing New Products To Fruition..He's a Nuclear Pysics Expert!....& Mr.Ludwig, now This Gentlemen Has International Ties Over Seas, So It's Easy To Imagine Who He Can Bring To The Table!!!!!
""Heavy Weight Mr.Su, Now This Guy Here Is The Mastermind Behind The Scenes Of The Isotope R&D Manufacturing...He Works For Pharma GIANTS"" Like Bristol-Myers Squibb..Also Working
As a Senior Scientist For Several Bio-Technology Firms, Including NeoRx, Nycomed-Amersham,And Cellectar, He Developed Various Radiopharmaceuticals, Very Impressive Savvy Scientist Players!!..,& Last But Not Lease,
Mr. Korenko.,Very..,Very Astute Intelligent Man Who Was Educated At One Of The Most Prestigious Colleges In The World ""OXFORD"" He Was Selected As a White House Fellow For The Department Of Defense Reporting To Secretary Cap Weinberger...,So Yes This Guy Has Inside Connection o The Dept Of Health And Human Services Players!!!!!
Board Of Director's:
"" Mr.Spivak What Can I Say Other Than They Call Him The Billion Dollar Man""...,Billions In Acquisitions..,Mergers..,Financing's This Guy Has Worked With Bigg Oil Mobil..,Merrill Lynch If Anybody That Can Find The $$$$$$ This Guy Can!!!!
""Mr.Cadwell Very Successful Business Man Players Co-Founded Cadwell Laboratories Privately Owned Business In 1979 And Serves As The President Till This Day....Very Savvy Business Mind Indeed!!
Visit Mr. Cadwell's Website Here Players
""Mr.Clement With His Influence Has Already Had Successful FDA Clearance With His Atrial Fibrillation Monitor, And As The CEO Of Two Very Successful Business's.., We Are Very Lucky To Have This Guy On The Board Players!
Advisory Boards:
Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Center and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, Ca.
Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.
Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard's Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography(CT).
"I am delighted to be appointed to Chair the newly formed Medical Advisory Board (MAB) for AMIC. I anticipate rapid expansion of our MAB, initially focusing on the potential for the Company's brachytherapy products," said Pressman.
James C. Katzaroff, CEO of AMIC, stated, "It is with great pleasure I welcome Dr. Pressman's guidance in assisting the Company to enter the commercial marketplace with its therapeutic products. As AMIC expands beyond the distribution and the production of stable and diagnostic radioisotopes, to the manufacturing of therapeutic products with AMIC's own product line, Dr. Pressman will be instrumental in providing a nationally-recognized practitioner's perspective and expertise that will enable the company to meet the growing needs of a dynamic nuclear medicine marketplace."
"" Mr.Fisher Is The Isotope GURU"..,Holds Several Patents Including Patents Licensed By AMIC For It's Brachytherapy Products...,Very Knowledgeable In The Isotope Field Of Technology!!!!.,& Finally Mr. Waltar Who By All Rights Holds The Key To ADMD He Has Ties With India & China, And Will Be Instrumental In Bringing The Y-90 RadioGel™ Device To Market Players!!!!!
Research & Development:
Does Nuclear Medicine Save Lives?
Yes! More than 20 million Americans benefit each year from nuclear medicine procedures used to diagnose and treat a wide variety of diseases. The use of radiation in these procedures— with low risks—offers a safe and cost-effective means to provide doctors with information that would otherwise require exploratory surgery, necessitate more costly and invasive procedures or simply be unavailable. The risks of not performing a needed medical exam are usually much greater than the risks of the radiation exposures associated with the exam.
Nuclear medicine can be used to:
determine whether or not organs are functioning normally,
show whether the blood supply to the heart is adequate,
detect cancers at an early stage,
determine the extent of cancer and assess the response of cancer to treatment,
discover whether the heart can pump blood adequately,
identify abnormal brain lesions without exploratory surgery,
detect whether the brain is receiving an adequate blood supply and if brain cells are functioning or not,
check whether or not kidneys are functioning normally and whether the stomach is emptying properly,
ascertain lung function and bone density and
locate a bone fracture before it can be seen on an X-ray.
Brachytherapy:
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.
AMIC’s Brachytherapy Products
AMIC has exclusively licensed Yttrium-90 (Y-90) polymer composite technology from *Battelle Memorial Institute, developed at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers.
Subject to receipt of all required regulatory approvals from the FDA in the United States and analogous regulators outside of the United States, AMIC plans to introduce a new Y-90-based brachytherapy product line for a range of applications for the delivery of a prescribed dose of radiation to a target site.
•Y-90 RadioGel™ device - combines Y-90 particles with a polymer carrier that may be injected directly into the tumor.
•Y-90 Fast-Resorbable Polymer Seeds - Y-90 contained within a polymer seed, as opposed to metal or glass. This product would be used in place of treating cancers with currently marketed titanium or glass seeds.
•Y-90 Polymer Topical Paste – designed to be applied directly to tissue surfaces after surgical tumor removals (also referred to as “resections”) to treat residual tumor cells..
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, AMIC believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, AMIC’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. AMIC’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. AMIC’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. The Yttrium-90 beta-emissions travel only a short distance and has a short half life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
Products:
""The Cream Of The Crop Players Yttrium 90 RadioGel™ and Polymer Seeds, Is The Future Of Radioactive Brachytherapy, And Is What We Are Waiting On The FDA To Approve....With Battelle In Our Corner There Should Be No Problem Getting This Done....(More On Battelle In a Moment)
Advanced Medical Isotope Corporation has obtained an exclusive license to eight (8) patents for injectable RadioGel™ technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The Agreement grants AMIC an exclusive license to make, have made, use and sell a RadioGel™ system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres directly into tumor tissues. The solution warms to body temperature quickly after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place. High-energy beta particles from Yttrium-90 efficiently irradiate cancer cells within the targeted volume but very little radiation escapes. This feature maximizes the overall radiation dose to cancer cells while minimizing radiation exposure and associated side-effects in nearby normal tissues.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 microspheres and the radiogel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost.
The late Dr. Robert Schenter, AMIC's Former Chief Scientific Officer, stated, "AMIC continues to develop the Yttrium-90 RadioGel™ line with Pacific Northwest National Laboratory, operated by Battelle. We believe that this product optimizes treatment of radiation-resistant tumors in vivo. We expect the RadioGel™ to become a therapeutic agent that provides physicians with the ability to effectively treat tumors that cannot be removed surgically or that cannot be treated by any other means."
According to AMIC the primary advantages of licensing these Yttrium-90 radiogels are multifold:
This treatment provides the ability to deliver a highly localized radiation therapy without irradiating nearby normal tissues - thereby achieving desired high therapeutic indices.
We are able to provide dose homogeneity within a solid tumor.
Because Yttrium-90 is a beta emitter, there is improved radiation safety for hospital personnel who prepare and handle the product.
Medical Isotopes:
AMIC is developing innovative approaches to the use, production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic applications. A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease.
The cornerstone equipment selected for the AMIC Production Facility is a proton linear accelerator. This proton linear accelerator is designed to replace large and cyclotron systems with significant infrastructure and utility requirements, such as electrical and air-handling, for the production of positron emitting isotopes. Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography. AMIC believes that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.
From 2008 through 2013, AMIC manufactured and sold F-18 FDG from its Production Facility in its local region around Kennewick, WA. F-18 is an important isotope in the radiopharmaceutical industry, and is primarily synthesized into fluorodeoxyglucose (FDG) for use in positron emission tomography (PET) scans. FDG is the primary PET imaging isotope. It is used for medical and diagnostic purposes, such as cancer detection, heart imaging, and brain imaging. AMIC’s linear accelerator is capable of producing a variety of isotopes and future manufacturing and sales could expand beyond F-18 FDG. AMIC’s accelerator is currently off-line for maintenance and is expected to resume operations in late 2014.
The FDA has 120 days in which to make a decision, though the period will be extended for any time AMIC requires to respond to FDA requests for additional information.
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.
AMIC's rights for the newly issued patent arise from its license from Battelle, under which AMIC exclusively licensed technologies developed at Pacific Northwest National Laboratory and the University of Utah for its proposed brachytherapy products. The patent awarded, US 8,821,364 B2, relates to AMIC's brachytherapy seed product and is entitled: Brachytherapy Seed with Fast Dissolving Matrix for Optimal Delivery of Radionuclides to Cancer Tissue. AMIC will support Battelle in further patent protection for additional markets consistent with AMIC's overall global commercialization strategy.
Battelle, has acquired approximately 11% of AMIC’s outstanding Common Stock. Battelle is a leading international science and technology enterprise that explores emerging areas of science and develops and commercializes technology.
""Mega Gorilla DD Coming Here On ADMD...<<<<Stay Tuned Players!
""Nibble..,Nibble..,Nibble Here On ADMD""
ADMD Looking Good Monny.....Consolidating Nicely In This Tight Range .002-.0022~
You Got That Right BT.....There's a Mega Whale @ .0018 With 47K To Spread Around, So If He Moves Up^ On The Bid You Can Bet Folks Will Be Scrambling To Get In Here On ADMD!
""Bidding 26.2MILLY! @ .0018!"", 47K+ Big$$$.
This May Be The Last Day To Buy In The .002-.0025 Range Here On ADMD....Past Trend Of Consolidation Could Be Broken By The End Of The Day,So We Will Be Adding As Much As We Can In The Range Above The Entire Day!
""Welcome MIA"".....ADMD Consolidated Nicely Today After Recent Lows Of .0012 And 3 Days Of Massive Gains Over 120% Bouncing Smooth Off Of Support Of .002....We May See Another Day Of Consolidation Before The Next Leg Up^.... CONGRATS!!!!!.., To Those Who Cashed Out & Moved On.....Now Let The Bigg Boyz Take It From Here!!!!!
""Tru Dat""..,Excellent Point~
Thanks For Sharing That Here On VOIS!...>>>>>I Believe Time Has Come For Meaty T-Bone News Fella's Not Based On That Tweet, But Based On The End Of The Month Is Near & News Must Flowwwwwww~~~~~~~~~~
""Boing..,Boing..,Boing Bounce""..>>>>ADMD WOW!!!!
You Are Right, However I Don't Think We Will See .002 Today, But We Will Test It Sometime This Week Before We Start The Next Leg Up^ Here On ADMD!
""It Takes Them All To Make a Market Bro""....Flippers..,Swingers..,Short Termers & Long Termers!...They All Provide a Great Service Here In The Market Of ADMD!
Flippers & Swingers Provide Liquidity, And Short Termers & Long Termers Provide Stability, So Right Know We Are Seeing Plenty Of Liquidity In The Market Which My Friend Is GOOD!
Let The Swingers Sell Away & Let The Flippers Flip Away, Because At The End The LONGS Will Prevail, Because We Are Right There To Suck Up All They Are Selling!!!!
It's Looking Like Consolidation For a Few Days Here....ADMD Perfect Loading Opps Between .002-.0025, I've Been Wrong Before But We'll See~
""We'll Be Knocking On The Door Of .003's Very Shortly Here On ADMD!